Market reaction
Mangoceuticals Inc. (NASDAQ:MGRX) saw its stock surge 70% in premarket trading after the company disclosed rapid early demand for its injectable testosterone replacement therapy offering and lower marketing costs. Management reported a 336% month-over-month increase in sales of the $99-per-month TRT program and said customer acquisition costs fell by 54%.
Program details and timing
The Dallas-based telemedicine operator began selling the injectable TRT product in mid-December. The firm describes the $99 monthly plan as an all-inclusive package that covers doctor visits, medical consultations, laboratory testing and interpretation, and the prescribed medication.
Business model and brands
MangoRx runs a telehealth platform that markets health and wellness products under the MangoRx and PeachesRx brands. Company materials indicate TRT is expected to serve as the main growth engine going forward, and leadership has signaled plans to allocate resources toward advancing both injectable and oral formulations, including PRIME by MangoRx, powered by Kyzatrex.
Management view
Founder and CEO Jacob Cohen said: "We are encouraged by this initial customer demand and sales acceleration in our injectable TRT product, which we believe demonstrates the value of our innovative approach to men’s hormone health and underscores TRT as our key strategic focus."
Market context and prescribing
The company cited an external estimate that places the global testosterone replacement therapy market at roughly $2.11 billion to $2.2 billion in 2025, with a projected compound annual growth rate near 3.9%, per The Business Research Company’s Testosterone Replacement Therapy Global Market Report. MangoRx states that all of its products are prescribed through licensed healthcare providers following medical evaluations and laboratory testing.
Implications for stakeholders
The immediate market response reflects investor interest in rapid program uptake and improved marketing efficiency. For healthcare and telemedicine sectors, the results point to demand for bundled remote care products that include diagnostic and prescribing services. For capital markets, the stock move underscores sensitivity to early commercial traction metrics for small-cap telehealth companies.